2019 Health for Humanity Report
A young boy smiling in front of blue building
A young boy smiling in front of blue building

Mlolongo Blue Box Clinic, Kenya.

Better Health for All
Better Health for All Tackling the World’s Toughest Health Challenges
  • HC-BP-240a.1
    Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index

Overcoming Antimicrobial Resistance

The spread of drug-resistant pathogens, known as antimicrobial resistance (AMR), is a growing public health concern. Overuse of antibiotics, or not using them as prescribed, contributes to growth of resistant bacteria, which renders antibiotics less effective or ineffective. It is estimated that by 2050, AMR infections could cause 10 million deaths annually.9 Johnson & Johnson has a longstanding commitment to develop and responsibly deploy innovative technologies and treatments to combat the growing threat of AMR on multiple fronts.

In 2019, we joined the U.S. Centers for Disease Control and Prevention’s AMR Challenge to combat antimicrobial resistance by submitting an actionable commitment for change. The AMR Challenge is a way for governments, private companies, and non-governmental organizations worldwide to make formal commitments that further the progress against antimicrobial resistance. Read our commitment on the AMR Challenge page.

Recognized for our leadership in AMR
Johnson & Johnson is proud to be recognized for the second time as a leader among our peers in the fight against AMR in the 2020 Antimicrobial Resistance Benchmark. The independent report from the Access to Medicine Foundation evaluates 30 pharmaceutical companies on their efforts to bring AMR under control. The Access to Medicine Foundation is an independent, nonprofit research organization based in the Netherlands.

Our performance was recognized in four core categories: Research & Development (R&D), Responsible Manufacturing, Appropriate Access, and Stewardship. Johnson & Johnson is making the second-largest R&D investment in relevant disease areas as identified by the Benchmark and is stewarding one of the largest antimicrobial pipelines to ensure antimicrobials remain a backbone of modern medicine.

These efforts are clearly exemplified in our work to tackle drug-resistant TB (DR-TB). DR-TB is responsible for one-third of all AMR-related deaths and is the world’s only airborne drug-resistant infection. Currently, a third of all people with DRTB— approximately 300,000 individuals—are not aware they are infected, posing a major threat to public health and global health security. See our section on Eradicating Tuberculosis.

9 https://www.healthpolicy-watch.org/no-time-to-wait-amr-could-cause-10-million-deaths-annually-by-2050-warns-un-report/

Back To Transforming Mental Healthcare Up Next Enhancing Access to Healthcare
You are leaving jnj.com and entering a third-party site. This link is provided for your convenience, and Johnson & Johnson disclaims liability for content created or maintained by third parties.